|
TNFRSF11B
|
0.090 |
AlteredExpression
|
disease |
BEFREE |
In addition, JWH-015 treatment inhibited bone destruction as evident from micro-CT scanning and bone analysis on the harvested joints and modulated serum RANKL and OPG levels.
|
31139184 |
2019 |
|
TNFRSF11B
|
0.090 |
AlteredExpression
|
disease |
BEFREE |
The RANK / RANKL / OPG system participates in the regulation of osteolytic activity under normal conditions, and its alteration has been associated with greater bone destruction, and also with tumor growth.
|
29680857 |
2018 |
|
TNFRSF11B
|
0.090 |
Biomarker
|
disease |
BEFREE |
OPG might be considered as a diagnostic and prognostic biomarker of periodontal bone destruction.
|
25814780 |
2015 |
|
TNFRSF11B
|
0.090 |
Biomarker
|
disease |
BEFREE |
The RANK/RANKL/OPG pathway is well known for bone destruction in skeletal metastases but has also been implicated in osteoclast-independent roles in tumorigenesis and de novo metastasis.
|
24785095 |
2014 |
|
TNFRSF11B
|
0.090 |
Biomarker
|
disease |
BEFREE |
Furthermore, CREB signaling in cancer cells regulated the gene expression of PTHrP, MMPs, and OPG, which are closely involved in cancer metastasis and bone destruction.
|
20599715 |
2010 |
|
TNFRSF11B
|
0.090 |
Biomarker
|
disease |
BEFREE |
Interface tissue fibroblasts are able to produce RANKL, OPG, and cathepsin K and may contribute indirectly and directly to pathologic periprosthetic collagenolysis and bone destruction.
|
15801030 |
2005 |
|
TNFRSF11B
|
0.090 |
GeneticVariation
|
disease |
BEFREE |
To study the effects of osteoclast-targeted therapies, such as osteoprotegerin (OPG) and pamidronate, on joint inflammation and bone destruction using a tumor necrosis factor alpha (TNF alpha)-transgenic mouse model.
|
11920416 |
2002 |
|
TNFRSF11B
|
0.090 |
Biomarker
|
disease |
BEFREE |
Our data identify TRANCE and OPG as key cytokines whose deregulation promotes bone destruction and supports myeloma growth.
|
11562486 |
2001 |
|
TNFRSF11B
|
0.090 |
Biomarker
|
disease |
BEFREE |
To understand the involvement of osteoclastogenesis inhibitory factor (OCIF), also called osteoprotegerin (OPG), in the pathogenesis of bone destruction in rheumatoid arthritis (RA), we investigated the cytokine network involved in the production of OCIF by human fibroblast-like synovial (HFLS) cells from a patient with RA.
|
11685652 |
2001 |